That's not all the bad news for Wyeth today. In yet another blow, the company and its partner ViroPharma have stopped dosing patients with HCV-796, a Phase II hepatitis C drug candidate. The decision follows a review by the joint safety review board of safety data accumulated to date, which shows elevated liver enzyme levels in some patients after eight weeks or more of therapy with HCV-796 with pegylated interferon and ribavirin. Two study subjects experienced serious adverse events and dropped out of the trial. The companies said they will analyze safety data in order to determine the fate of HCV-796.
- see this release